Eli Lilly says its weight loss drug can reduce diabetes risk

Eli Lilly’s Zepbound anti-obesity drug can significantly reduce the risk of developing Type 2 diabetes in people with excess weight and high blood sugar, the company revealed on Tuesday.

The study found that Zepbound, when taken weekly for more than three years, reduced the risk of Type 2 diabetes by 94% compared to a placebo.

However, the benefits were primarily maintained while patients were on the drug, as some weight was regained and diabetes progression increased after stopping treatment.

The new benefits add to the popularity of the already much sought-after weight loss drug. Other properties include reducing heart attack risks and improving sleep apnea.

These benefits may encourage more insurers to cover the costly drugs, which can cost over $1,000 a month.

Eli Lilly’s sales of Zepbound and another diabetes drug, Mounjaro, have significantly boosted the company’s financial performance, leading to a rise in its stock value.